Ivacaftor/Lumacaftor

N/A

Report date: 2022/01/24 09:15:14
First In Class

Base Information

Drug NameIvacaftor/Lumacaftor
Drug Alias Name艾伐卡托/LumacaftorIvacaftor and LumacaftorLumacaftor and IvacaftorLumacaftor/IvacaftorOrkambi
ClassificationSmall molecules
Mechanisms of ActionP-glycoprotein 1 inhibitorsCystic fibrosis transmembrane conductance regulator stimulants
TargetsCystic fibrosis transmembrane conductance regulatorP-glycoprotein 1
Therapy Area/IndicationsCystic Fibrosis
Global Approved IndicationsCystic Fibrosis
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2015/07/02
Country/TerritoryCanadaUnited StatesEU
CombinationsYes LumacaftorIvacaftor
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesVertex Pharmaceuticals Incorporated
China Registration ClassN/A

Develop Information

Active CompaniesVertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (Ireland) Ltd
Inactive CompaniesN/A
Active IndicationsCystic Fibrosis
Inactive IndicationsN/A

Other Information

ATC CodeR07AX30
Related LinksWikipediaKEGG